# Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

> **NCT00628108** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 69 (actual)

## Conditions studied

- Allergic Rhinitis
- Chronic Urticaria

## Interventions

- **DRUG:** Levocetirizine 1.25 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00628108
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00628108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00628108, "Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00628108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*